© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 12, 987-994,
June 21, 2000
© 2000 Oxford University Press
REPORTS |
Effects of c-erbB2 Overexpression on the Drug Sensitivities of Normal Human Mammary Epithelial Cells
Affiliations of authors: M. S. Orr, Gene Logic Inc., Gaithersburg, MD; P. M. O'Connor, Agouron Pharmaceuticals, Inc., San Diego, CA; K. W. Kohn, Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, Bethesda, MD.
Correspondence to: Michael S. Orr, Ph.D., Gene Logic Inc., 708 Quince Orchard Rd., Gaithersburg, MD 20878 (e-mail: morr{at}genelogic.com).
Background: Overexpression of the gene c-erbB2, which encodes a receptor tyrosine kinase, in breast tumors has been linked with either increased or decreased response of breast cancer patients to various therapies. In breast cancer cell lines, overexpression of exogenous c-erbB2 sometimes alters drug sensitivities but sometimes has no effect. To avoid the genetic complexities associated with established cancer cell lines, normal human mammary epithelial cells (HMECs) were studied to determine whether c-erbB2 overexpression by itself would alter chemosensitivity. Methods: HMECs were designed to overexpress c-erbB2, and these cells were then evaluated for alterations in chemosensitivity. Results: HMECs overexpressing c-erbB2 failed to show any alterations in chemosensitivity to a panel of chemotherapeutic agents, as indicated by 95% confidence intervals on growth curves of cells treated with or without the agent of interest. With the use of fluorescence-activated cell sorting to enrich for HMECs overexpressing c-erbB2 on their surface, an 85% pure population of cells was isolated and their chemosensitivity was evaluated. Again, the cells failed to display any alterations in chemosensitivity. Conclusions: These results suggest that overexpression of c-erbB2 is not sufficient by itself to induce changes in chemosensitivity. Cellular studies using normal human cells in which the complexity of the system can be carefully controlled by the addition of one, two, or even more genes associated with cancer development may provide valuable information about how the products of the genes interact with each other and which combinations are critical in regulating chemosensitivity.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Menendez, L. Vellon, R. Colomer, and R. Lupu Effect of {gamma}-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene J Natl Cancer Inst, November 2, 2005; 97(21): 1611 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kauraniemi, T. Kuukasjarvi, G. Sauter, and A. Kallioniemi Amplification of a 280-Kilobase Core Region at the ERBB2 Locus Leads to Activation of Two Hypothetical Proteins in Breast Cancer Am. J. Pathol., November 1, 2003; 163(5): 1979 - 1984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kauraniemi, M. Barlund, O. Monni, and A. Kallioniemi New Amplified and Highly Expressed Genes Discovered in the ERBB2 Amplicon in Breast Cancer by cDNA Microarrays Cancer Res., November 1, 2001; 61(22): 8235 - 8240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yamauchi, V. Stearns, and D. F. Hayes When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2334 - 2356. [Abstract] [Full Text] [PDF]
|
|